UBS: maintains "buy" rating on GIANT BIOGENE (02367) and raises target price to HK$82
The company believes that the revenue and profit forecast for the next two years will be higher due to strong performance during Women's Day.
UBS released a research report stating that it reaffirmed a "buy" rating for GIANT BIOGENE (02367), with a target price raised from 63.5 Hong Kong dollars to 82 Hong Kong dollars. The bank stated that with the strong performance of the flagship product collagen bars from COMFY and better-than-expected sales of the new "Focus Series" in the second half of last year, they are confident in the company's growth trajectory for this year. Preliminary data shows that the COMFY brand performed well in the ongoing Women's Day shopping festival.
UBS has raised its profit forecast for the company for the years 2024 to 2026 by 3% to 4% to reflect the latest revenue and profit guidance from last year, as well as higher revenue and profit forecasts for the next two years due to the strong performance during Women's Day.
Related Articles

Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.

Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.

Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


